Literature DB >> 24320158

A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids.

Tracy L Brewer1, Margie Collins.   

Abstract

PURPOSE: The purpose of this review is to heighten the awareness of the increased use and risks of synthetic cannabinoids (SCs) and associated clinical manifestations among adolescents and young adults.
CONCLUSIONS: Reviewed case studies suggest that the use of SCs have unpredictable negative psychological and physiological effects. Predominant manifestations reported were anxiety, agitation, paranoia, hallucinations, tachycardia, nausea and vomiting, and diaphoresis. PRACTICE IMPLICATIONS: Nurses provide the most direct and supportive care to patients who present for medical treatment after the use of SCs. Knowledge of clinical manifestations can facilitate supportive management of patients suspected of SCs use.
© 2013, Wiley Periodicals, Inc.

Entities:  

Keywords:  Adolescent; clinical manifestation; review; synthetic cannabinoid; synthetic marijuana; young adult

Mesh:

Substances:

Year:  2013        PMID: 24320158     DOI: 10.1111/jspn.12057

Source DB:  PubMed          Journal:  J Spec Pediatr Nurs        ISSN: 1539-0136            Impact factor:   1.260


  15 in total

1.  Synthetic and Other Drug Use among High School Students: The Role of Perceived Prevalence, Access, and Harms.

Authors:  Katrina J Debnam; Shonali Saha; Catherine P Bradshaw
Journal:  Subst Use Misuse       Date:  2018-04-06       Impact factor: 2.164

2.  Rapid analysis of synthetic cannabinoids using a miniature mass spectrometer with ambient ionization capability.

Authors:  Qiang Ma; Hua Bai; Wentao Li; Chao Wang; R Graham Cooks; Zheng Ouyang
Journal:  Talanta       Date:  2015-04-24       Impact factor: 6.057

3.  Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication.

Authors:  Ahmet Kırgız; Havva Kaldırım
Journal:  Int Ophthalmol       Date:  2017-12-23       Impact factor: 2.031

4.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

5.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 6.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

7.  Designer drugs 2015: assessment and management.

Authors:  Michael F Weaver; John A Hopper; Erik W Gunderson
Journal:  Addict Sci Clin Pract       Date:  2015-03-25

Review 8.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.

Authors:  Cristina Miliano; Giovanni Serpelloni; Claudia Rimondo; Maddalena Mereu; Matteo Marti; Maria Antonietta De Luca
Journal:  Front Neurosci       Date:  2016-04-19       Impact factor: 4.677

9.  Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice.

Authors:  Andrea Ossato; Licia Uccelli; Sabrine Bilel; Isabella Canazza; Giovanni Di Domenico; Micol Pasquali; Gaia Pupillo; Maria Antonietta De Luca; Alessandra Boschi; Fabrizio Vincenzi; Claudia Rimondo; Sarah Beggiato; Luca Ferraro; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Fabio De-Giorgio; Matteo Marti
Journal:  Front Psychiatry       Date:  2017-08-04       Impact factor: 4.157

Review 10.  Emerging drugs of abuse: current perspectives on synthetic cannabinoids.

Authors:  Danièle Debruyne; Reynald Le Boisselier
Journal:  Subst Abuse Rehabil       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.